{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T23:08:35Z","timestamp":1768864115677,"version":"3.49.0"},"reference-count":38,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T00:00:00Z","timestamp":1768608000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Institute for Health and Care Research (NIHR) Cambridge Biomedical Research Centre","award":["NIHR203312"],"award-info":[{"award-number":["NIHR203312"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/Objectives: There is conflicting data on which factors predict progression events in active surveillance for early prostate cancer. Here, we explored the value of different clinicopathological variables and whether progression endpoint definitions impact predictive utility. Methods: Clinicopathological variables were extracted from the STRATified CANcer Surveillance (STRATCANs) prospective AS database and included biopsy features (core positivity, cancer core length, and percentage core involvement) and MRI features (Likert score, lesion size, and location), as well as baseline PSA density [PSAd] and Cambridge Prognostic Group (CPG). These were tested against AS endpoint definitions of (1) progression to \u2265CPG3, (2) any pathological progression and two definitions from the literature, (3) \u2265GG3 or change to treatment, and (4) \u2265GG4, metastasis or cancer-related mortality. Predictors were assessed using regression analysis. Results: Data from 296 men were included (median age, 66; follow-up, 5 years). Progression per definition (1\u20134) occurred in 46 (15.5%), 54 (18.2%), 84 (28.4%), and 10 (3.4%) men. In univariate analysis using Definition 1, no biopsy parameter was independently predictive of progression, while the MRI Likert score (p = 0.02) was the only significant imaging parameter. For Definition 2, core positivity (p = 0.003) and MRI Likert score (p = 0.01) were significant predictors in univariate analyses, while for Definition 3, tumour core length (p = 0.005), core positivity (p = 0.002), and MRI Likert score (p = 0.003) were all predictive in univariate analyses. In multivariate analysis, however, the only consistent independent predictor was PSAd, regardless of endpoint definition. No variables predicted Definition 4 progression. Conclusions: AS endpoint selection appears to define which variables predict progression. Using progression to \u2265CPG 3 as an unambiguous AS endpoint, neither biopsy nor MRI variables added incremental value in predicting progression. PSAd, however, appears to be a robust and independent generalisable progression predictor.<\/jats:p>","DOI":"10.3390\/cancers18020292","type":"journal-article","created":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T09:57:02Z","timestamp":1768816622000},"page":"292","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Impact of Endpoint Definitions on Predictors of Progression in Active Surveillance for Early Prostate Cancer"],"prefix":"10.3390","volume":"18","author":[{"given":"Kieran","family":"Sandhu","sequence":"first","affiliation":[{"name":"Department of Surgery, University of Cambridge, Cambridge CB2 0QQ, UK"},{"name":"Cambridge Prostate Cancer Research and Clinical Trials Group, Cambridge CB2 0QQ, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0550-4657","authenticated-orcid":false,"given":"Artitaya","family":"Lophatananon","sequence":"additional","affiliation":[{"name":"Division of Population Health, Health Services Research and Primary Care Centre, University of Manchester, Manchester M13 9PL, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4722-4207","authenticated-orcid":false,"given":"Vincent J.","family":"Gnanapragasam","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of Cambridge, Cambridge CB2 0QQ, UK"},{"name":"Cambridge Prostate Cancer Research and Clinical Trials Group, Cambridge CB2 0QQ, UK"},{"name":"Department of Urology, Cambridge University Hospitals, Cambridge CB2 0QQ, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/JU.0000000000002757","article-title":"Clinically Localized Prostate Cancer: AUA\/ASTRO Guideline, Part I: Introduction, Risk Assessment, Staging, and Risk-Based Manage-ment","volume":"208","author":"Eastham","year":"2022","journal-title":"J. Urol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent","volume":"86","author":"Cornford","year":"2024","journal-title":"Eur. Urol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1200\/JCO.2015.65.7759","article-title":"Active Surveillance for the Management of Localized Prostate Cancer (Cancer Care Ontario Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement","volume":"34","author":"Chen","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1200\/JCO.2014.55.1192","article-title":"Long-term follow-up of a large active surveillance cohort of patients with prostate cancer","volume":"33","author":"Klotz","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.eururo.2019.12.017","article-title":"Active Surveillance of Grade Group 1 Prostate Cancer: Long-term Outcomes from a Large Prospective Cohort","volume":"77","author":"Tosoian","year":"2020","journal-title":"Eur. Urol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1097\/JU.0000000000000713","article-title":"Long-Term Outcomes of Active Surveillance for Prostate Cancer: The Memorial Sloan Kettering Cancer Center Experience","volume":"203","author":"Carlsson","year":"2020","journal-title":"J. Urol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.eururo.2016.03.048","article-title":"Long-term Results of Active Surveillance in the G\u00f6teborg Randomized, Population-based Prostate Cancer Screening Trial","volume":"70","author":"Godtman","year":"2016","journal-title":"Eur. Urol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"405","DOI":"10.4111\/icu.2020.61.4.405","article-title":"Prediction of pathologic upgrading in Gleason score 3+4 prostate cancer: Who is a candidate for active surveillance?","volume":"61","author":"Pham","year":"2020","journal-title":"Investig. Clin. Urol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1007\/s00330-021-08332-8","article-title":"MRI grading for the prediction of prostate cancer aggressiveness","volume":"32","author":"Boschheidgen","year":"2022","journal-title":"Eur. Radiol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.eururo.2012.01.050","article-title":"Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: Incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades","volume":"61","author":"Epstein","year":"2012","journal-title":"Eur. Urol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s00345-008-0343-3","article-title":"Prediction of Gleason score upgrading in low-risk prostate cancers diagnosed via multi (> or = 12)-core prostate biopsy","volume":"27","author":"Hong","year":"2009","journal-title":"World J. Urol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1007\/s11255-022-03250-0","article-title":"Adverse upgrading and\/or upstaging in contemporary low-risk prostate cancer patients","volume":"54","author":"Flammia","year":"2022","journal-title":"Int. Urol. Nephrol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1002\/pros.23873","article-title":"The pathological upgrading after radical prostatectomy in low-risk prostate cancer patients who are eligible for active surveillance: How safe is it to depend on bioptic pathology?","volume":"79","author":"Verep","year":"2019","journal-title":"Prostate"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.juro.2015.08.087","article-title":"Outcomes of Active Surveillance for Clinically Localized Prostate Cancer in the Prospective, Multi-Institutional Canary PASS Cohort","volume":"195","author":"Newcomb","year":"2016","journal-title":"J. Urol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s00345-014-1348-8","article-title":"Predicting the risk of harboring high-grade disease for patients diagnosed with prostate cancer scored as Gleason \u2264 6 on biopsy cores","volume":"33","author":"Seisen","year":"2015","journal-title":"World J. Urol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/bju.14800","article-title":"Using prognosis to guide inclusion criteria, define standardised endpoints and stratify follow-up in active surveillance for prostate cancer","volume":"124","author":"Gnanapragasam","year":"2019","journal-title":"BJU Int."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Light, A., Lophatananon, A., Keates, A., Thankappannair, V., Barrett, T., Dominguez-Escrig, J., Rubio-Briones, J., Benheddi, T., Olivier, J., and Villers, A. (2022). Development and External Validation of the STRATified CANcer Surveillance (STRATCANS) Multivariable Model for Predicting Progression in Men with Newly Diagnosed Prostate Cancer Starting Active Surveillance. J. Clin. Med., 12.","DOI":"10.3390\/jcm12010216"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1111\/bju.16666","article-title":"The 5-year results of the Stratified Cancer Active Surveillance programme for men with prostate cancer","volume":"135","author":"Gnanapragasam","year":"2025","journal-title":"BJU Int."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.euros.2022.12.013","article-title":"Prospective Implementation and Early Outcomes of a Risk-stratified Prostate Cancer Active Surveillance Follow-up Protocol","volume":"49","author":"Thankapannair","year":"2023","journal-title":"Eur. Urol. Open Sci."},{"key":"ref_20","unstructured":"National Institute for Health and Care Excellence (2025, November 25). Prostate Cancer: Diagnosis and Management 2021. Available online: https:\/\/www.nice.org.uk\/guidance\/ng131."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.eururo.2025.03.019","article-title":"Magnetic Resonance Imaging-led Risk-adapted Active Surveillance for Prostate Cancer: Updated Results from a Large Cohort Study","volume":"88","author":"Englman","year":"2025","journal-title":"Eur. Urol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Sushentsev, N., Li, I.G., Xu, G., Warren, A.Y., Hsu, C.Y., Baxter, M., Panchal, D., Kastner, C., Fernando, S., and Pazukhina, E. (2025). Predicting Active Surveillance Failure for Patients with Prostate Cancer in the Magnetic Resonance Imaging Era: A Multicentre Transatlantic Cohort Study. Eur Urol Oncol.","DOI":"10.1016\/j.euo.2025.06.012"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"83","DOI":"10.21037\/tau.2017.12.24","article-title":"Active surveillance for prostate cancer: A systematic review of contemporary worldwide practices","volume":"7","author":"Kinsella","year":"2018","journal-title":"Transl. Androl. Urol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.eururo.2021.05.001","article-title":"Reliability of Serial Prostate Magnetic Resonance Imaging to Detect Prostate Cancer Progression During Active Surveillance: A Systematic Review and Meta-analysis","volume":"80","author":"Peyrottes","year":"2021","journal-title":"Eur. Urol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1111\/bju.12858","article-title":"Medium-term oncological outcomes for extended vs saturation biopsy and transrectal vs transperineal biopsy in active surveillance for prostate cancer","volume":"115","author":"Thompson","year":"2015","journal-title":"BJU Int."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.juro.2014.09.094","article-title":"Extended followup and risk factors for disease reclassification in a large active surveillance cohort for localized prostate cancer","volume":"193","author":"Welty","year":"2015","journal-title":"J. Urol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.eururo.2013.02.020","article-title":"Medium-term outcomes of active surveillance for localised prostate cancer","volume":"64","author":"Selvadurai","year":"2013","journal-title":"Eur. Urol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.euo.2024.09.008","article-title":"Determining Long-term Prostate Cancer Outcomes for Active Surveillance Patients Without Early Disease Progression: Implications for Slowing or Stopping Surveillance","volume":"8","author":"Shee","year":"2025","journal-title":"Eur. Urol. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.eururo.2019.12.009","article-title":"Role of Changes in Magnetic Resonance Imaging or Clinical Stage in Evaluation of Disease Progression for Men with Prostate Cancer on Active Surveillance","volume":"77","author":"Chesnut","year":"2020","journal-title":"Eur. Urol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1007\/s00330-020-07256-z","article-title":"Natural history of prostate cancer on active surveillance: Stratification by MRI using the PRECISE recommendations in a UK cohort","volume":"31","author":"Giganti","year":"2021","journal-title":"Eur. Radiol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1016\/j.euo.2025.01.008","article-title":"Are Patients with Prostate Imaging Reporting and Data System 5 Lesions Eligible for Active Surveillance? A Multicentric European Study","volume":"8","author":"Peyrottes","year":"2025","journal-title":"Eur. Urol. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1910038","article-title":"MRI-Targeted, Systematic, and Combined Biopsy for Prostate Cancer Diagnosis","volume":"382","author":"Ahdoot","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/j.eururo.2016.06.007","article-title":"A Decade of Active Surveillance in the PRIAS Study: An Update and Evaluation of the Criteria Used to Recommend a Switch to Active Treatment","volume":"70","author":"Bokhorst","year":"2016","journal-title":"Eur. Urol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.eururo.2025.06.012","article-title":"Active Surveillance for Screen-detected Low- and Intermediate-risk Prostate Cancer: Extended Follow-up up to 25 Years in the GOTEBORG-1 Trial","volume":"88","author":"Palmstedt","year":"2025","journal-title":"Eur. Urol."},{"key":"ref_35","first-page":"709.e9","article-title":"PSA density as a dynamic prognostic marker of biopsy grade progression during active surveillance","volume":"43","author":"Gusev","year":"2025","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Moser, A.M., Wang, M., Zamani, A., Meah, S., Daignault-Newton, S., Labardee, C., Dybas, N., Clapper, J., Lane, B.R., and Borza, T. (2025). Application of the STRATCANS Criteria to the MUSIC Prostate Cancer Active Surveillance Cohort: A Step Towards Risk-Stratified Active Surveillance. Cancers, 17.","DOI":"10.3390\/cancers17183032"},{"key":"ref_37","unstructured":"National Cancer Control Programme (2026, January 14). HSE National Clinical Guideline: Active Surveillance for Patients with Prostate Cancer, Available online: https:\/\/www2.healthservice.hse.ie\/files\/495\/."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.eururo.2021.12.007","article-title":"Systematic Review of Active Surveillance for Clinically Localised Prostate Cancer to Develop Recommendations Regarding Inclusion of Intermediate-risk Disease, Biopsy Characteristics at Inclusion and Monitoring, and Surveillance Repeat Biopsy Strategy","volume":"81","author":"Willemse","year":"2022","journal-title":"Eur. Urol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/2\/292\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T10:04:54Z","timestamp":1768817094000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/2\/292"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,17]]},"references-count":38,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["cancers18020292"],"URL":"https:\/\/doi.org\/10.3390\/cancers18020292","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,17]]}}}